Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 15 Life Science VC (Venture Capital) Funds in Italy in January 2026

Last updated: Jan 2026 A list of 15 VC (Venture Capital) funds that invest in Life science startups based in Italy. We rank investors based on the number of investments they made in Life science companies from Italy. We update this investor list every month.

Top 15 Life Science VC (Venture Capital) Funds in Italy in January 2026

Investor	Life Science Italy investments
Sofinnova Partners	4
Indaco Venture Partners	2
Principia SGR	2
Claris Ventures	1
Italian Angels for Growth	1
Gaiae International	1
MCF Holding	1
Deep Blue Ventures	1
JDRF T1D Fund	1
AbbVie Biotech Ventures	1
CDP Venture Capital	1
LIFTT	1
Club degli Investitori	1
Roche Venture Fund	1
ReItaly21	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

DNA Script — DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.
AAVantgarde Bio — AAVantgarde Bio is developing gene therapies for inherited retinal disorders.
Excelsior Sciences — Rebuilding the World, From the Bottom Up

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Funding Round
Italy, Switzerland, United States

Portfolio highlights

Easy Rain — Easyrain pioneers active safety systems to prevent aquaplaning. We develop virtual sensors and hardware solutions to save lives on hazardous low-grip roads.
CamGraPhIC — Our platform supports the ever-increasing data traffic demand with high-performing and low-power consumption electro-optical engines.
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.

Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.

Investment focus

Health Care, Biotechnology, Software
Funding Round, Series A, Seed
Italy, United States, United Kingdom

Portfolio highlights

KLISBio — KLISBio is a medtech company currently developing a variety of regenerative medicine implantable products leveraging the power of silk fibroin to promote an endogenous repair of human soft tissues.
ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
WISE — WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

Claris Ventures is a venture capital firm supporting the best scientists in building successful life sciences companies that will impact people's lives

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Series A, Series B
Italy, United Kingdom

Portfolio highlights

NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
ALKemist Bio — ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune system, the company aims to overcome resistance and deliver more effective, lasting treatments for solid tumors.
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.

IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.

Investment focus

Software, E-Commerce, Health Care
Seed, Angel, Series A
Italy, United States, United Kingdom

Portfolio highlights

ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
Rubedo Life Sciences — Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.
Restorative Neurotechnologies — Siamo un'azienda di dispositivi medicali certificati per la riabilitazione cognitiva ed il trattamento di disturbi cognitivi post ictus.

Gaiae International is a leading importer and exporter of fruits and vegetables.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

MCF Holding is a holding company of financial investments that engages in the management of events, retail, and real estate business.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

Deep Blue Ventures is an international holding company that acquires, manages, and scales the next generation of online brands.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, Canada, France

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, Italy

Portfolio highlights

Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.

CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Funding Round
Italy, United States, United Kingdom

Portfolio highlights

Cubbit — Cubbit is secure encrypted cloud storage with a difference. A distributed cloud that is 100% private and green. Join the Swarm.
Titan4 — Titan4 provides products and services based on research combining different satellite data and sources for applications. They also provide development and integration, InSAR data analysis and data mining, geological analysis, and deep learning analytic services.
Dog Heroes — Dog Heroes delivers home recipes of fresh food, perfectly portioned to every dog's need. Only high-quality local ingredients are used in tailor-made portions that are ready to serve. Customers will find 55% meat of exclusively Italian origin in the company's recipes, balanced with vegetables, vitamins, and mineral salts. Dog Heroes doesnot use any chemical additives or preservatives.

A not-only-profit operating investment company, eager to create a bridge between innovative ideas, territory and capital.

Investment focus

Biotechnology, Software, Information Technology
Seed, Series A, Funding Round
Italy, United Kingdom, France

Portfolio highlights

QSensAto — QSensAto is a quantum sensing company specializing in the development and research of integrated vapor cells and quantum atomic sensors.
Agate Sensors — Agate Sensors offers equipment manufacturers advanced sensors that detect, identify, and classify people, vital signs, objects, and more. Their sensors come in a range of sizes, from single pixel devices to full matrix devices, and are produced using standard CMOS production processes, making them both cost-effective and efficient.
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.

Club degli Investitori (Investors Club) is a network of investors and business angels that invest on early-stage SMEs and startups. The community of 300+ Members (entrepreneurs, CEOs, executive managers) actively scouts for investing opportunities on SMEs & startups and invests with a minimum ticket of €200k. The Club supports business byinvesting capital and by leveraging the Members' network and experience.Club degli Investitori is supported by Unicredit and KPMG Italy.

Investment focus

Health Care, E-Commerce, Information Technology
Seed, Series A, Series B
Italy, Switzerland, United Kingdom

Portfolio highlights

Ephos — Designing and manufacturing glass-based integrated photonic circuits that power the most advanced classical and quantum devices
Stema — It serves as a platform for hiring engineers
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

ReItaly21 is an investment firm.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

Investors by industry

Community

Artificial intelligence